Pfizer plans to cut price for Prevnar 13 in poor countries; Allergan schedules shareholder meeting to approve Actavis buy;

@FiercePharma: Supreme Court pitches patent fight over $SHPG's Lialda after $TEVA ruling. Report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Actavis explains the recall of generic Neurontin was limited to 2,000 bottles shipped to one customer. Story | Follow @EricPFierce

> Pfizer ($PFE) is cutting the price for its pneumococcal vaccine Prevnar 13 by 6% in developing countries as part of its commitment to a global vaccines alliance. Story

> Allergan ($AGN) scheduled a March 10 meeting to get shareholder approval for its purchase of Actavis ($ACT). Article

> Bayer struck a licensing and distribution deal with Hungarian drugmaker Richter to sell the company's contraceptive patch in Europe. More

> Sen. Elizabeth Warren (D-MA) proposed funding initiatives through the National Institutes of Health (NIH) by fining Big Pharma companies for illegal practices. Story

> Oklahoma is asking the U.S. Supreme Court to delay the execution of three death-row inmates as it tries to obtain a different sedative for lethal injections. More

Medical Device News

@FierceMedDev: Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: IYCMI yesterday: Medtronic and Covidien to close $43B merger today with Irish High Court approval. Article | Follow @EmilyWFierce

> Medtronic sets sights on hospital and product innovation post-Covidien deal close. News

> Hoffman pleads guilty to murdering former Boston Sci exec in Minneapolis suburb. Report

> J&J launches new, smaller, more precise vascular stapler for thoracic surgery. Article

Biotech News

@FierceBiotech: The Special K connection: Naurex spotlights another promising NMDA depression drug. Report | Follow @FierceBiotech

@JohnCFierce: I see R&D costs climbed to $7.1B at $PFE last year. Probably same again in '15. Citing Phase III costs. Release | Follow @JohnCFierce

@DamianFierce: Per earnings statement, $NVS finally submitted the COPD combo QVA149 + NVA237 to the FDA late last year. Release | Follow @DamianFierce

> Google, Biogen team up on MS research: report. Item

> Obama wants to pour $1.2B into antibiotic R&D. Report

> Singapore's MerLion eyes partner for Phase III of Finafloxacin urinary infection trials. Article

Biotech Research News

> UCSD team turns the PKC tumor theory upside down. Item

> Psoriasis researchers identify a lineup of suspect proteins behind disease progression. More

> International team tags a key brain pathway for hypoglycemia. Report

> Stanford scientists use modified RNA to rejuvenate aging cells. Story

> Alzheimer's investigators at Gladstone find a drug target for guarding memories. Article

Pharma Manufacturing News

> BASF invests $63M in PVP manufacturing operations. More

> Novo will soon open plant in Russia. Article

> Hospira recalls more saline after human hair found in a bag. Report

> FDA slaps down another Indian plant, adding to the industry's woes. Story

> Australia's TGA issues updated guidelines on drug supply chain releases. Item

And Finally… A new study found that the longer people have high cholesterol, the greater their risk for developing heart disease. Story (sub. req.)

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.